Spots Global Cancer Trial Database for A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Official Title: A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Study ID: NCT04860466
Conditions
Interventions
Study Description
Brief Summary: The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B, monotherapy dose expansion.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 104, Minneapolis, Minnesota, United States
Local Institution - 103, Omaha, Nebraska, United States
Local Institution - 101, Houston, Texas, United States
Local Institution - 102, Seattle, Washington, United States
Local Institution - 201, Toronto, Ontario, Canada
Local Institution - 202, Montreal, Quebec, Canada
Hopital Claude Huriez, Lille, , France
CHU Montpellier - Hôpital Saint Eloi, Montpellier CEDEX 5, , France
Hopital Lyon Sud, Pierre Benite, , France
Local Institution - 401, Madrid, , Spain
Local Institution - 403, Malaga, , Spain
Local Institution - 402, Salamanca, , Spain
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
